Kuipers Harmjan, Lambrecht Bart N
Department of Pulmonary Medicine, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.
Vaccine. 2005 Aug 31;23(37):4577-88. doi: 10.1016/j.vaccine.2005.04.031.
Atopic asthma is a chronic inflammatory disease of the airways, characterized by airway hyperreactivity and mucus hypersecretion that result in intermittent airway obstruction. This chronic inflammation is the result of an aberrant Th2-mediated response to innocuous environmental proteins. The prevalence of this disease has increased dramatically in the industrialized world in the last decades. Current treatment is mainly based on pharmacological interventions, which control the disease but are not curative. Although the etiology is not completely understood, it becomes increasingly clear that dendritic cells play an important role in both the sensitization phase and maintenance of the disease. In this review, we explore the different possibilities to exploit dendritic cell vaccines in order to prevent the development of (or inhibit established) atopic asthma.
特应性哮喘是一种气道慢性炎症性疾病,其特征为气道高反应性和黏液分泌过多,导致间歇性气道阻塞。这种慢性炎症是对无害环境蛋白的异常Th2介导反应的结果。在过去几十年中,这种疾病在工业化国家的患病率急剧上升。目前的治疗主要基于药物干预,虽能控制病情但无法治愈。尽管其病因尚未完全明确,但越来越清楚的是,树突状细胞在疾病的致敏阶段和维持过程中都起着重要作用。在本综述中,我们探讨了利用树突状细胞疫苗预防(或抑制已有的)特应性哮喘发展的不同可能性。